Tumor necrosis factor alpha-induced protein 3
The TNFAIP3 gene encodes a cytokine which is involved in the TNF pathway. Mutations cause autosomal dominant pediatric Behçet-like disease.
Genetests:
Related Diseases:
References:
1. |
Dixit VM et al. (1990) Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin.
|
2. |
Wertz IE et al. (2015) Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation.
|
3. |
Zhou Q et al. (2016) Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease.
|
4. |
Liu X et al. (2014) Interleukin-17 (IL-17)-induced microRNA 873 (miR-873) contributes to the pathogenesis of experimental autoimmune encephalomyelitis by targeting A20 ubiquitin-editing enzyme.
|
5. |
Vande Walle L et al. (2014) Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis.
|
6. |
Ma L et al. (2014) Role of A20 in interferon-α-mediated functional restoration of myeloid dendritic cells in patients with chronic hepatitis C.
|
7. |
Lu TT et al. (2013) Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme.
|
8. |
Matmati M et al. (2011) A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis.
|
9. |
Shembade N et al. (2010) Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes.
|
10. |
Ferch U et al. (2009) Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.
|
11. |
Compagno M et al. (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.
|
12. |
Kato M et al. (2009) Frequent inactivation of A20 in B-cell lymphomas.
|
13. |
Schmitz R et al. (2009) TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.
|
14. |
Braggio E et al. (2009) Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia.
|
15. |
Song XT et al. (2008) A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression.
|
16. |
Coornaert B et al. (2008) T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20.
|
17. |
Wolfrum S et al. (2007) The protective effect of A20 on atherosclerosis in apolipoprotein E-deficient mice is associated with reduced expression of NF-kappaB target genes.
|
18. |
Vendrell JA et al. (2007) A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells.
|
19. |
Boone DL et al. (2004) The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses.
|
20. |
Wertz IE et al. (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling.
|
21. |
Cook SA et al. (2003) A20 is dynamically regulated in the heart and inhibits the hypertrophic response.
|
22. |
O'Reilly SM et al. (2003) Regulation of Toll-like receptor 4 signalling by A20 zinc finger protein.
|
23. |
Lee EG et al. (2000) Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice.
|
24. |
Opipari AW et al. (1990) The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein.
|
Update: Aug. 14, 2020